Details

Autor(en) / Beteiligte

• Chan, Xin Hui S
• Haeusler, Ilsa L
• Win, Yan Naung
• Pike, James
• Hanboonkunupakarn, Borimas
• Hanafiah, Maryam
• Lee, Sue J
• Djimdé, Abdoulaye
• Fanello, Caterina I
• Kiechel, Jean-René
• Lacerda, Marcus VG
• Ogutu, Bernhards
• Onyamboko, Marie A
• Siqueira, André M
• Ashley, Elizabeth A
• Taylor, Walter RJ
• White, Nicholas J
• Beeson, James G.

Titel

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis

Ist Teil von

• PLoS medicine, 2021-09, Vol.18 (9), p.e1003766

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2021

Quelle

EZB*

Beschreibungen/Notizen

• Amodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria. Data on the cardiovascular effects of amodiaquine are scarce, although transient effects on cardiac electrophysiology (electrocardiographic QT interval prolongation and sinus bradycardia) have been observed. We conducted an individual patient data meta-analysis to characterise the cardiovascular effects of amodiaquine and thereby support development of risk minimisation measures to improve the safety of this important antimalarial. Studies of amodiaquine for the treatment or prevention of malaria were identified from a systematic review. Heart rates and QT intervals with study-specific heart rate correction (QTcS) were compared within studies and individual patient data pooled for multivariable linear mixed effects regression. While caution is advised in the use of amodiaquine in patients aged [greater than or equal to]12 years with concomitant use of heart rate-reducing medications, serious cardiac conduction disorders, or risk factors for torsade de pointes, there have been no serious cardiovascular events reported after amodiaquine in widespread use over 7 decades. Amodiaquine and structurally related antimalarials in the World Health Organization (WHO)-recommended dose regimens alone or in ACTs are safe for the treatment and prevention of malaria.